UNSPSC 51432903: Fosinoprilat

This classification denotes an ace inhibitor with the molecular formula C23H34NO5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S312EY6ZT8, chemically known as sq 27,519 but generally known as fosinoprilat, which bears US NIH Compound Identifier 62956. European Medicines Agency schedules Fosinoprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07800MIG. The term FOSINOPRILAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30).

UNSPSC 51432903 Fosinoprilat, a Commodity code, covers pharmaceutical active ingredients and finished medications supplied to state and local health systems, emergency services, and pharmacy benefit programs. Recent state and local solicitations under this code show procurement of advanced life support medications and generic multi-source pharmaceuticals distributed through authorized wholesalers to public health agencies and state employee benefit plans. The issuing bodies span municipal fire and rescue services, state health and human services agencies, and multistate cooperative purchasing alliances coordinating procurement across multiple jurisdictions. Work involves supplying branded and generic medications with strict expiration-date warranties, maintaining cGMP and Drug Supply Chain Security Act compliance, and arranging just-in-time delivery to emergency services and pharmacy benefit networks.

Activity appears across Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) due April 8, 2026, for advanced life support medications including epinephrine, adenosine, labetalol, and diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus renewal options. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) and comply with cGMP and DSCSA certification. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) in March 2026 to explore direct-to-manufacturer prescription fulfillment programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Tampa solicitation carries a 5 percent SLBE bid discount; MMCAP pricing evaluation weights price competitiveness at 75 percent and administrative compliance at 20 percent.